COCP News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CO

Volume

22.29K

Next Earnings

November 13th

Loading chart

CO

COCPCocrystal Pharma, Inc. Common Stock

COCP

Pay with—

Available Balance0.00

CO

Mkt Cap

$19.8M

Volume

22.29K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial ResultsCocrystal Pharma completed enrollment in the first cohort of a Phase 1b challenge study for CDI-988, an oral protease inhibitor for norovirus prevention and treatment. The company received FDA Fast Track designation for CDI-988 and an initial $225,000 NIH SBIR grant for influenza A/B antiviral development. Q1 2026 revenue was $225,000 from grant income, with net loss of $2.3 million and cash position of $4.7 million.GlobeNewswire Inc. · May 15, 2026

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026Cocrystal Pharma announced that its oral norovirus protease inhibitor CDI-988 will be presented at the ICAR 2026 conference in Prague. The company will present Phase 1 data and updates from an ongoing Phase 1b challenge study at Emory University School of Medicine. CDI-988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infections, with no approved antiviral therapies or vaccines currently available for this indication.GlobeNewswire Inc. · Feb 19, 2026

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus ConferenceCocrystal Pharma presented CDI-988, a potential first oral antiviral for norovirus infection, at the International Calicivirus Conference. The drug shows promising broad-spectrum activity and has received FDA clearance for a Phase 1b human challenge study.GlobeNewswire Inc. · Sep 12, 2025

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment ConferenceCocrystal Pharma's CFO and co-CEO James Martin will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference, discussing their clinical-stage antiviral drug development efforts.GlobeNewswire Inc. · Sep 3, 2025

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344Cocrystal Pharma is extending enrollment in a Phase 2a study of its influenza antiviral candidate CC-42344 due to unexpectedly low influenza infection rates among study participants. The drug showed a favorable safety and tolerability profile, but the low infection rates hindered the analysis of its antiviral activity.GlobeNewswire Inc. · Dec 31, 2024

Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?Zacks Investment Research · Jun 7, 2024

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsBOTHELL, Wash., May 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.GlobeNewswire Inc. · May 13, 2024

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsBOTHELL, Wash., March 28, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.GlobeNewswire Inc. · Mar 28, 2024

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza AFeedback provides greater clarity on regulatory requirements for planned Phase 2b trialGlobeNewswire Inc. · Mar 19, 2024

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastBOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces that President and co-CEO Sam Lee, PhD will discuss progress in developing the novel, broad-spectrum PB2 inhibitor CC-42344 in an oral presentation, “Taking a new route: Development of novel inhaled and oral influenza antiviral, CC-42344” at the World Vaccine Congress West Coast on Tuesday, November 28, 2023 at 3:20 p.m. Pacific Time. The conference is being held November 27-30 at the Santa Clara Convention Center in Santa Clara, Calif.GlobeNewswire Inc. · Nov 9, 2023

to start trading

CO

COCPCocrystal Pharma, Inc. Common Stock

COCP

Pay with—

Available Balance0.00

Your PositionYou don't own any COCP yet.

Related Tickers

Earnings